MX2014012362A - Composición prebiótica y métodos de uso. - Google Patents

Composición prebiótica y métodos de uso.

Info

Publication number
MX2014012362A
MX2014012362A MX2014012362A MX2014012362A MX2014012362A MX 2014012362 A MX2014012362 A MX 2014012362A MX 2014012362 A MX2014012362 A MX 2014012362A MX 2014012362 A MX2014012362 A MX 2014012362A MX 2014012362 A MX2014012362 A MX 2014012362A
Authority
MX
Mexico
Prior art keywords
prebiotic
bifidobacteria
subject
prebiotic composition
mixture
Prior art date
Application number
MX2014012362A
Other languages
English (en)
Spanish (es)
Inventor
David S Newburg
Zhuoteng Yu
Original Assignee
Trustees Boston College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Boston College filed Critical Trustees Boston College
Publication of MX2014012362A publication Critical patent/MX2014012362A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/529—Infantis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2014012362A 2012-04-13 2013-03-13 Composición prebiótica y métodos de uso. MX2014012362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623868P 2012-04-13 2012-04-13
PCT/US2013/030764 WO2013154725A1 (en) 2012-04-13 2013-03-13 Prebiotic compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2014012362A true MX2014012362A (es) 2015-05-07

Family

ID=49328018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012362A MX2014012362A (es) 2012-04-13 2013-03-13 Composición prebiótica y métodos de uso.

Country Status (6)

Country Link
US (1) US20150265661A1 (https=)
EP (1) EP2836218A4 (https=)
JP (1) JP2015512936A (https=)
CN (1) CN104507483A (https=)
MX (1) MX2014012362A (https=)
WO (1) WO2013154725A1 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651067T3 (es) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2885977A1 (en) * 2013-12-19 2015-06-24 Agriculture and Food Development Authority (TEAGASC) An oligosaccharide-enriched composition having immune-modulatory and anti-adhesion properties
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
PL3209673T5 (pl) 2014-10-24 2023-10-23 Glycom A/S Mieszaniny hmo
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP3212197A4 (en) 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
AR103260A1 (es) * 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AU2018205072B2 (en) * 2014-12-23 2020-05-21 Cj Bioscience, Inc. Immune modulation
EP3288389A4 (en) 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
PL3368046T3 (pl) * 2015-10-28 2022-11-28 Glycom A/S Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
EP3377071B1 (en) * 2015-11-17 2024-01-10 Glycom A/S Human milk oligosaccharides for treating antibiotic associated complications
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3389668A4 (en) 2015-12-15 2019-08-21 Glycom A/S MIXTURE OF HMOS
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
EP3429604A1 (en) 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
DK3452050T3 (da) * 2016-05-05 2023-02-20 Glycom As Composition comprising hmos for the treatment of noninfectious diarrhoea
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
EP4548925A3 (en) 2016-07-01 2025-07-09 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
SG10202100843TA (en) 2016-07-28 2021-03-30 Fonterra Cooperative Group Ltd Dairy product and process
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018155995A1 (ko) * 2017-02-27 2018-08-30 한국생명공학연구원 시아릴락토오스를 유효성분으로 포함하는 항균용 조성물
JP2020513014A (ja) * 2017-04-07 2020-04-30 チルドレンズ ホスピタル メディカル センター ２’−フコシルラクトース化合物による炎症性腸疾患の治療
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
CN111356461A (zh) * 2017-10-04 2020-06-30 加利福尼亚大学董事会 免疫调节性低聚糖
KR102741265B1 (ko) * 2017-11-30 2024-12-11 글리콤 에이/에스 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception
AU2019232004A1 (en) * 2018-03-08 2020-10-01 Plexus Worldwide Llc Compositions and methods for skin renewal
CN108935698A (zh) * 2018-09-11 2018-12-07 内蒙古伊利实业集团股份有限公司 一种预防小儿腹泻疾病的营养组合物及应用
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
BE1027078A9 (nl) * 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
CN110257299B (zh) * 2019-07-11 2022-06-10 锦州医科大学 一种阴沟肠杆菌在促进反刍动物生长的应用
CN112869168B (zh) * 2019-11-29 2023-06-06 内蒙古伊利实业集团股份有限公司 可提高胃肠道免疫能力的益生菌益生元组合物及其应用
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
CN111363671B (zh) * 2020-02-26 2023-07-21 天津医科大学 一种肠道厌氧微生物培养瓶及其制备方法
WO2021197492A1 (zh) * 2020-04-03 2021-10-07 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖
CN112075637B (zh) * 2020-04-27 2023-05-23 合生元（广州）健康产品有限公司 一种减少肠道气体产生的组合物
CN112841543A (zh) * 2021-01-28 2021-05-28 重庆周师兄餐饮文化有限公司 一种麻辣脆的加工方法
MX2023008202A (es) 2021-01-29 2023-07-18 Nestle Sa Mezcla de hmo y bifidobacteria.
CN112890200B (zh) * 2021-03-08 2021-11-12 合生元（广州）健康产品有限公司 用于促进低体重婴幼儿生长追赶的一种营养组合物
WO2022223430A1 (en) * 2021-04-19 2022-10-27 Dsm Ip Assets B.V. A composition of enzymes and human milk oligosaccharides
AU2022307441A1 (en) * 2021-07-09 2024-01-25 Société des Produits Nestlé S.A. Uses of bifidobacterium longum transitional microorganism
CN113796545B (zh) * 2021-09-13 2022-09-13 合生元（广州）健康产品有限公司 调节肠道免疫功能的母乳低聚糖组合物及其应用
KR102411242B1 (ko) * 2021-10-18 2022-06-22 큐티스바이오 주식회사 클렙시엘라 아에로제네스의 피부 상태 개선 용도
DK202200588A1 (en) 2022-06-20 2024-02-23 Dsm Ip Assets Bv Mixture of fucosylated HMOs
CN115920013A (zh) * 2022-11-15 2023-04-07 合生元（广州）健康产品有限公司 乳源成分在降低单增李斯特菌引起的感染风险中的应用
CN116042486B (zh) * 2023-02-22 2024-11-08 高邮市人民医院 一种用于治疗动脉粥样硬化的复合菌制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630452B2 (en) * 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US20060127546A1 (en) * 2004-08-27 2006-06-15 Purac Biochem B.V. Use of glycine and/or glycine derivatives as antibacterial agent against gram negative bacterial pathogens in foods and/or drinks
ES2651067T3 (es) * 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
FI20096400A0 (fi) * 2009-12-28 2009-12-28 Suomen Punainen Risti Veripalv Veriryhmästatuksen käyttö I
CN102858191A (zh) * 2010-04-27 2013-01-02 N.V.努特里奇亚 6’-唾液酸化乳糖在婴儿和幼儿营养物中的用途
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
CA2822219C (en) * 2010-12-31 2020-12-29 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
PT2672844E (pt) * 2011-02-10 2015-02-04 Nestec Sa Modulação do crescimento de bifidobactérias utilizando uma combinação de oligossacáridos identificados no leite humano

Also Published As

Publication number Publication date
EP2836218A1 (en) 2015-02-18
JP2015512936A (ja) 2015-04-30
US20150265661A1 (en) 2015-09-24
CN104507483A (zh) 2015-04-08
EP2836218A4 (en) 2015-10-21
WO2013154725A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
MX2014012362A (es) Composición prebiótica y métodos de uso.
US9603876B2 (en) Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
US10155015B2 (en) Probiotic compositions for use in the treatment of bowel diseases
JP6494859B2 (ja) 細菌株を含む組成物
JP5905032B2 (ja) 腸管内微生物叢の回復および再構成のためのシンバイオティクス組成物
CN103987393B (zh) 包括与益生菌联合的n-乙酰半胱氨酸和/或微胶囊化的胃保护性溶菌酶的组合物
US12128077B2 (en) Strains, composition and method of use
US20240293483A1 (en) Probiotic composition for the treatment of increased intestinal permeability
EP2415475B1 (en) Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
WO2015093937A1 (en) Lactobacillus salivarius for the treatment of mastitis
CN117678765A (zh) 一种益生菌低聚糖组合物及其应用与含有该组合物的奶粉
CN118574923A (zh) 柯林斯菌新菌种及其药物组合物
CN114728028A (zh) 包括具有增强的持久性的新微生物的组合物、新微生物和益生元的协同组合
KR20240093392A (ko) 질병 치료를 위한 조성물 및 방법
Yang et al. A clinical primer of the role of gut microbiome in health and disease
JP6837992B2 (ja) 非伝達性の抗生物質耐性を有し、同じ治療適応症を有する乳酸菌および／またはビフィズス菌の同時使用と組合せた、特定の治療活性を有する抗生物質の使用
CN119947716A (zh) 用于治疗或预防受试者肠道菌群失调的一氧化碳释放分子（corm）或其组合物
WO2022161928A1 (en) Probiotic composition comprising lactobacillus salivarius and bifidobacterium longum and its uses
US20230310519A1 (en) Use of adlercreutzia bacteria for the treatment of inflammatory diseases
RU2735717C1 (ru) Штамм Bifidobacterium bifidum, используемый в качестве пробиотика
TWI897570B (zh) 長雙歧桿菌及其用於降低血液中氧化三甲胺及增加腸道中艾克曼嗜黏蛋白菌含量的用途
WO2025248095A1 (en) Probiotic strain lactobacillus gasseri for vaginal infections
CN121852271A (zh) 益生大肠杆菌CP57 (Escherichia coli CP57)及其应用
Singh Evaluation of Potential Probiotic Strains of Lactobacillus Reuteri for Anti-hyperoxaluria and Anti-hypercholesterolemic Activity